| 1. |
Ruff CT, Braunwald E. The evolving epidemiology of acute coronary syndromes. Nat Rev Cardiol 2011;8:140-7.
|
| 2. |
Haghjooyjavanmard S, Nematbakhsh M, Monajemi A, Soleimani M. Von Willebrand factor, C-reactive protein, nitric oxide, and vascular endothelial growth factor in a dietary reversal model of hypercholesterolemia in rabbit. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:91-5.
|
| 3. |
Alian Z, Hashemipour M, Dehkordi EH, Hovsepian S, Amini M, Moadab MH, et al. The effects of folic acid on markers of endothelial function in patients with type 1 diabetes mellitus. Med Arh 2012;66:12-5.
|
| 4. |
Yang Z, Ming XF. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 2006;4:53-65.
|
| 5. |
Cuzzocrea S, Mazzon E, Serraino I, Lepore V, Terranova ML, Ciccolo A, et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 2001;30:1-12.
|
| 6. |
Beck WR, Botezelli JD, Pauli JR, Ropelle ER, Gobatto CA. Melatonin has an ergogenic effect but does not prevent inflammation and damage in exhaustive exercise. Sci Rep 2015;5:18065.
|
| 7. |
Altun A, Yaprak M, Aktoz M, Vardar A, Betul UA, Ozbay G. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci Lett 2002;327:143-5.
|
| 8. |
Domínguez-Rodríguez A, Abreu-González P, García MJ, Sanchez J, Marrero F, de Armas-Trujillo D. Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res 2002;33:248-52.
|
| 9. |
Yaprak M, Altun A, Vardar A, Aktoz M, Ciftci S, Ozbay G. Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. Int J Cardiol 2003;89:103-7.
|
| 10. |
Rodella LF, Favero G, Foglio E, Rossini C, Castrezzati S, Lonati C, et al. Vascular endothelial cells and dysfunctions: Role of melatonin. Front Biosci (Elite Ed) 2013;5:119-29.
|
| 11. |
Tutuncu NB, Batur MK, Yildirir A, Tutuncu T, Deger A, Koray Z, et al. Melatonin levels decrease in type 2 diabetic patients with cardiac autonomic neuropathy. J Pineal Res 2005;39:43-9.
|
| 12. |
Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res 2007;42:319-22.
|
| 13. |
Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009;73:411-8.
|
| 14. |
Marçola M, da Silveira Cruz-Machado S, Fernandes PA, Monteiro AW, Markus RP, Tamura EK. Endothelial cell adhesiveness is a function of environmental lighting and melatonin level. J Pineal Res 2013;54:162-9.
|
| 15. |
Tailleux A, Gozzo A, Torpier G, Martin-Nizard F, Bonnefont-Rousselot D, Lemdani M, et al. Increased susceptibility of low-density lipoprotein to ex vivo oxidation in mice transgenic for human apolipoprotein B treated with 1 melatonin-related compound is not associated with atherosclerosis progression. J Cardiovasc Pharmacol 2005;46:241-9.
|
| 16. |
Tailleux A, Torpier G, Bonnefont-Rousselot D, Lestavel S, Lemdani M, Caudeville B, et al. Daily melatonin supplementation in mice increases atherosclerosis in proximal aorta. Biochem Biophys Res Commun 2002;293:1114-23.
|